MARS in the treatment of liver failure: Controversies and evidence

被引:11
作者
Chiu, A.
Fan, S. T.
机构
[1] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[2] Queen Mary Hosp, Intens Care Unit, Hong Kong, Hong Kong, Peoples R China
关键词
MARS; albumin dialysis; liver support; liver failure;
D O I
10.1177/039139880602900703
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Molecular Adsorbent Recirculation System (MARS) is a form of extracorporeal detoxification system used as an artificial liver support system. Numerous studies have been published on the topic, with the majority of them describing the capability of MARS in removing albumin-bound toxins and improving systemic hemodynamics. Whether such improvement could be translated into survival benefit is still uncertain, given the paucity of randomized controlled trials available. The outcome of patients receiving MARS treatment is difficult to analyze because liver failure patients constitute a heterogeneous population and different subgroups carry different prognoses. An evidence-based recommendation on the timing of MARS initiation is not available and currently MARS is usually commenced for hyperbilirubinemia or presence of complications of liver failure. MARS is in general a safe procedure, but there are still potential complications that need to be cautioned, along with various operative issues that are worth attention. The future prospects of MARS would rely on the completion of adequately powered randomized controlled trials.
引用
收藏
页码:660 / 667
页数:8
相关论文
共 49 条
[1]  
Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
[2]   Results of a phase I trial evaluating a liver support device utilizing albumin dialysis [J].
Awad, SS ;
Swaniker, F ;
Magee, J ;
Punch, J ;
Bartlett, RH .
SURGERY, 2001, 130 (02) :354-362
[3]  
Bregman H., 1994, HDB DIALYSIS, P149
[4]  
CHEN S, 2002, LIVER S2, V22, pS48
[5]   Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation - a pilot study [J].
Choi, JY ;
Bae, SH ;
Yoon, SK ;
Cho, SH ;
Yang, JM ;
Han, JY ;
Ahn, BM ;
Chung, KW ;
Sun, HS ;
Kim, DG .
LIVER INTERNATIONAL, 2005, 25 (04) :740-745
[6]   Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion [J].
Covic, A ;
Goldsmith, DJA ;
Gusbeth-Tatomir, P ;
Volovat, C ;
Dimitriu, AG ;
Cristogel, F ;
Bizo, A .
LIVER INTERNATIONAL, 2003, 23 :21-27
[7]   Surgical treatment of malignant liver tumours [J].
DeMatteo, RP ;
Fong, YM ;
Blumgart, LH .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 1999, 13 (04) :557-574
[8]   Early allograft dysfunction after liver transplantation -: A definition and predictors of outcome [J].
Deschênes, M ;
Belle, SH ;
Krom, RAF ;
Zetterman, RK ;
Lake, JR .
TRANSPLANTATION, 1998, 66 (03) :302-310
[9]   Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure [J].
Di Campli, C ;
Santoro, MC ;
Gaspari, R ;
Merra, G ;
Dal Verme, LZ ;
Zocco, MA ;
Piscaglia, AC ;
Di Gioacchino, G ;
Novi, M ;
Santoliquido, A ;
Flore, R ;
Tondi, P ;
Proietti, R ;
Gasbarrini, G ;
Pola, P ;
Gasbarrini, A .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (06) :2547-2550
[10]   The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure [J].
Di Campli, C ;
Zocco, MA ;
Gaspari, R ;
Novi, M ;
Candelli, M ;
Santoliquido, A ;
Flore, R ;
Tondi, P ;
Proietti, R ;
Gasbarrini, G ;
Pola, P ;
Gasbarrini, A .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (06) :2551-2553